Updated Jul 16, 2026
Shah Gaurav has filed 3 SEC Form 4 filings across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $102K. Lifetime open-market sales: $433K.
Gaurav Shah is the CEO of Rocket Pharmaceuticals, Inc., a biopharmaceutical company focused on developing gene therapies for rare pediatric diseases. Under his leadership, the company is advancing several promising therapies aimed at addressing critical health challenges in children.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 55.7K | $3.09 | $172K |
| 2026-05-26 | RCKT | ROCKET PHARMACEUTICALS, INC. | M — Option exercise | 76.5K | $1.69 | $129K |
| 2026-05-21 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 2.4K | $3.01 | $7K |
| 2026-05-14 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 2.7K | $3.61 | $10K |
| 2026-02-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 6.0K | $3.34 | $20K |
| 2026-02-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 12.3K | $3.31 | $41K |
| 2026-02-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | A — Grant or award | 286.0K | $0.00 | |
| 2025-08-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | F — Tax withholding / forfeiture | 2.2K | $3.05 | $7K |
| 2025-05-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 2.3K | $6.45 | $15K |
| 2025-05-16 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 3.6K | $6.53 | $24K |
| 2025-04-10 | RCKT | ROCKET PHARMACEUTICALS, INC. | P — Open-market purchase | 20.0K | $5.08 | $102K |
| 2024-11-25 | RCKT | ROCKET PHARMACEUTICALS, INC. | S — Open-market sale | 11.1K | $13.05 | $145K |
Gaurav Shah is the CEO of Rocket Pharmaceuticals, Inc., a biopharmaceutical company focused on developing gene therapies for rare pediatric diseases. Under his leadership, the company is advancing several promising therapies aimed at addressing critical health challenges in children.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($102K) and 8 open-market sales ($433K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Shah Gaurav profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.